PriMera Scientific
Medicine and Public Health
Volume 5 Issue 5 November 2024
ISSN: 2833-5627

Advancements in Pancreatic Cancer Management: From Epidemiology to Emerging Therapies

Type: Review Article
Received: October 19, 2024
Published: October 30, 2024

Citation:
Abiy Tereda. "Advancements in Pancreatic Cancer Management: From Epidemiology to Emerging Therapies". PriMera Scientific Medicine and Public Health 5.5 (2024): 24-37.

Abiy Tereda*

Department of Internal Medicine, Georgetown American University, USA

***Corresponding Author:** Abiy Tereda, MD, Department of Internal Medicine, Georgetown American University, USA.

Abstract

Pancreatic cancer represents a formidable challenge in modern oncology due to its dismal prognosis and substantial global burden. This comprehensive review examines the epidemiology, risk factors, pathophysiology, clinical presentation, diagnosis, treatment modalities, prognosis, and emerging therapies in pancreatic cancer. Epidemiological data reveal a concerning rise in incidence rates, particularly among younger cohorts and certain demographic groups. Known risk factors such as smoking, obesity, and family history are explored alongside emerging associations including changes in gut microbiota and metabolic disorders. Molecular pathways implicated in pancreatic carcinogenesis, including DNA adduct formation and genetic mutations such as KRAS, p53, and BRCA, are elucidated. The complex tumor microenvironment and stromal interactions are discussed, emphasizing their role in disease progression and therapeutic resistance. Clinical presentation, diagnostic modalities, staging systems, and challenges in early detection are outlined, followed by an overview of current treatment modalities including surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and palliative care. Prognostic factors and survival rates based on stage and treatment are analyzed, along with predictive biomarkers for prognosis and treatment response. Emerging therapies and research directions, including precision medicine and immunotherapy, are explored, alongside considerations for quality of life, survivorship, and psychosocial support. The article concludes with a summary of key findings, implications for clinical practice and research, and future perspectives for pancreatic cancer management and treatment.

Introduction

Pancreatic cancer presents an imposing challenge to global health, characterized by its notoriously bleak prognosis and substantial contribution to cancer-related mortality. Indeed, the disease looms large on the healthcare landscape, with a staggering 57,600 individuals in the United States grappling with diagnoses in 2020 alone. This prevalence underscores the urgent imperative for effective interventions to stem the tide of this pernicious affliction, as echoed in the compelling discourse of scholarly works [1, 2].

The etiology of pancreatic cancer is intricately woven with a tapestry of risk factors, spanning both genetic predispositions and lifestyle influences. Smoking, obesity, and sedentary habits emerge as prominent culprits in the genesis of this malignancy, as illuminated by the esteemed American Cancer Society [3]. Meanwhile, the specter of familial history looms ominously, casting a long shadow of heightened susceptibility, as elucidated by the scholarly insights of Benzel and Fendrich [4]. Moreover, the epidemiological landscape is in flux, with a disconcerting uptick in diagnoses among younger cohorts in the United States [5], signaling a shifting paradigm that demands attention and action.

The insidious nature of pancreatic cancer, often stealthily advancing until reaching advanced stages, underscores the critical importance of early detection in altering the trajectory of the disease. Here, the promise of pioneering biomarkers and cutting-edge imaging modalities emerges as a beacon of hope, poised to revolutionize the diagnostic frontier and usher in an era of timelier interventions [6].

Furthermore, the role of lifestyle factors cannot be overstated in shaping the risk landscape of pancreatic cancer. Embracing lifestyle modifications, such as cultivating a balanced dietary regimen, engaging in regular physical activity, and eschewing deleterious habits like tobacco use and excessive alcohol consumption, holds immense promise as pivotal prophylactic measures in mitigating the risk burden of this formidable disease [7].

Pancreatic cancer stands as an implacable foe on the battleground of public health, necessitating a multifaceted approach that encompasses advances in early detection, a deeper understanding of risk factors, and the promotion of healthy lifestyle habits. Only through concerted efforts and unwavering commitment can we hope to turn the tide against this formidable adversary and offer a brighter outlook for those affected by its ravages.

Epidemiology and Risk Factors

Global incidence and mortality rates

Pancreatic carcinoma is the 12th most prevalent malignancy on a global scale, with a staggering 495,000 fresh diagnoses documented in the annals of 2020. The age-standardized incidence rate (ASIR) stands at a sobering 6.6 per 100,000 person-years, emblematic of the substantial burden it exerts on public health worldwide. Mortality statistics shadow the incidence figures closely, mirroring the disease's relentless onslaught with an age-standardized mortality rate (ASMR) holding steady at 6.6 per 100,000 person-years.

In the contiguous expanse of the United States, pancreatic cancer casts a somber shadow over the healthcare landscape, prognosticated to snatch away over 50,550 souls in the calendar year of 2023. This grim tally accounts for a staggering 8.3% of all cancer-related fatalities, positioning pancreatic carcinoma as the fourth most lethal cancer across genders. Such sobering statistics underscore the dire exigency for breakthroughs in the realms of early detection and therapeutic intervention.

These numerical depictions of despair serve as a clarion call, resounding with the urgency of the global struggle against pancreatic cancer. They illuminate the imperative for unceasing dedication to the pursuit of research and innovation, holding the promise of ushering in a brighter era for patients grappling with this insidious affliction on a worldwide scale [8, 9].

Age, gender, and racial disparities

Variations in age, gender, and racial backgrounds play a notable role in shaping the epidemiology of pancreatic cancer. Recent investigations have shed light on the impact of these factors on both the incidence and mortality rates associated with the disease.

Age: The likelihood of developing pancreatic cancer escalates with advancing age, with a predominant occurrence among individuals aged 65 years and older. However, an unsettling trend is emerging, marked by a rise in diagnoses among younger cohorts, particularly noticeable among young females [9].

Gender: While pancreatic cancer affects individuals of all genders, studies have indicated a marginally higher incidence rate among men. Nevertheless, there is evidence to suggest a notable uptick in the annual percentage change of incidence rates among women, signaling a noteworthy shift in the gender distribution of the ailment [10].

Racial Disparities: Clear disparities based on racial and ethnic backgrounds are evident in pancreatic cancer outcomes, with discernible variations in both incidence and mortality rates across diverse demographic groups. Notably, in the United States, Black individuals exhibit higher incidence rates in comparison to their White counterparts. The underlying factors contributing to these disparities span socioeconomic circumstances, access to healthcare resources, and genetic predispositions [11, 12].

These disparities underscore the imperative for tailored preventive measures, enhanced early detection protocols, and equitable dissemination of healthcare services. By addressing these discrepancies, there is a potential to enhance outcomes and minimize the burden of pancreatic cancer across all strata of society.

Known risk factors (smoking, obesity, family history, etc.)

Pancreatic cancer, renowned for its grim prognosis and formidable mortality rates, has been the subject of extensive scientific inquiry aimed at elucidating its risk factors. An exhaustive review of meta-analytical studies has delineated several pivotal factors that markedly elevate the likelihood of developing this lethal ailment. Chief among these is tobacco smoking, with compelling evidence substantiating its strong correlation with pancreatic cancer. Estimates suggest that a substantial proportion of pancreatic cancer cases—ranging from 11% to 32%—could be averted through the eradication of tobacco usage. Obesity, another modifiable risk element, along with chronic ailments such as pancreatitis, further compound the risk profile. Furthermore, familial history emerges as a critical determinant, suggesting the involvement of genetic predispositions. Intriguingly, protective factors have also been identified, including a history of allergies and heightened consumption of fruits or folate, which have the potential to mitigate the risk of pancreatic cancer.

The panorama of risk factors for pancreatic cancer is dynamic, with recent investigations broadening our comprehension of potential contributory elements. Anomalous metabolism of human microorganisms, blood type variations, and fluctuations in glucose and lipid levels have emerged as novel spheres of interest. These discoveries underscore the imperative of continuous research endeavors to refine our armamentarium for early detection and preventive interventions. As we persist in unraveling the intricate etiology of pancreatic cancer, it becomes increasingly apparent that a considerable proportion of cases may be preventable through lifestyle modifications and tailored interventions predicated on individual risk profiles [13, 14].

Emerging risk factors and associations

Pancreatic cancer remains one of the most challenging malignancies to diagnose and treat, with emerging research continually updating our understanding of its risk factors and associations. Recent studies have highlighted the significance of novel risk factors such as changes in gut microbiota, blood type, and metabolic disorders, which may interact with traditional risk factors to influence the development of pancreatic cancer [15]. These findings are crucial as they pave the way for more personalized approaches to risk assessment and prevention. Additionally, the role of genetic susceptibility and the potential for early detection through surveillance of high-risk groups are areas of intense investigation, offering hope for improved outcomes in the future.

As the scientific community delves deeper into the etiology of pancreatic cancer, the importance of a multifaceted approach to risk assessment becomes evident. Understanding the interplay between emerging and established risk factors is essential for developing targeted screening strategies and preventive measures. This comprehensive approach is reflected in the current literature, where a summary review of meta-analytical studies provides robust estimates of causative or preventive risk factors for pancreatic cancer, identifying areas where future research is likely to be rewarding1. Furthermore, the changing epidemiology of pancreatic cancer and new approaches to risk assessment underscores the dynamic nature of this field, necessitating ongoing research and adaptation of clinical practices [15, 16].

Pathophysiology of Pancreatic Cancer

Molecular pathways implicated in pancreatic carcinogenesis

DNA adducts represent modifications to the structure of DNA resulting from the binding of reactive molecules, which can arise from both internal metabolic processes and external chemical exposures. Within the context of pancreatic cancer, these adducts have the potential to induce mutations in key genes governing cellular proliferation and programmed cell death. Notably, oxidative stress, a prominent contributor to DNA adduct formation, emerges as a significant factor in the genesis of pancreatic malignancies. This stress can be exacerbated by pancreatic inflammation, a prevalent condition associated with heightened cancer susceptibility. Understanding the intricate interplay between genetic damage and the cellular milieu in the pathogenesis of pancreatic cancer is pivotal for devising novel strategies in both prevention and treatment [17].

The formation of DNA adducts occurs when reactive substances, such as those encountered in tobacco smoke or generated internally due to oxidative stress, bind to DNA molecules. Individuals possessing specific metabolic genotypes, particularly those linked to the N-acetyltransferase 1 (NAT1) slow genotype, exhibit elevated levels of these DNA adducts. This observation implies a genetic predisposition to the effects of carcinogenic exposures, potentially instigating the onset of pancreatic cancer via the accrual of genetic anomalies. Additionally, the genetic makeup of enzymes involved in detoxification, such as glutathione S-transferases and NAD(P)H quinone reductase-1, may influence adduct levels, accentuating the complexity of pancreatic cancer etiology and emphasizing the imperative of comprehending the underlying molecular mechanisms [18].

DNA adducts possess the capacity to induce mutations if inadequately repaired, resulting in aberrations within the DNA sequence during replication. Individuals harboring specific genetic variations may exhibit heightened susceptibility to these DNA adducts, thus augmenting their vulnerability to mutations in pivotal oncogenes like K-ras. Mutations within the K-ras gene serve as prominent drivers of pancreatic carcinogenesis, inciting the activation of downstream signaling pathways that foster cellular proliferation and survival, thereby contributing to the malignant transformation of pancreatic cells. The influence of genetic determinants on an individual's pancreatic cancer risk, coupled with their potential interaction with environmental exposures, illuminates the broader spectrum of pancreatic cancer pathogenesis and may furnish insights for future endeavors in early detection and tailored therapeutic interventions guided by individual genetic profiles [19].

Role of genetic mutations (e.g., KRAS, p53, BRCA) in tumor development

The significance of genetic mutations, including KRAS, p53, and BRCA, in the development of pancreatic cancer has been extensively investigated. KRAS mutations, in particular, stand out as prevalent genetic abnormalities often observed in pancreatic cancer cases. Activation of the KRAS oncogene serves as a central driver in promoting cellular proliferation and survival, thus contributing significantly to the initiation and progression of pancreatic carcinogenesis [19].

Moreover, mutations in the tumor suppressor gene p53 are commonly identified in pancreatic cancer samples. Dysfunction of p53 disrupts vital cellular processes like DNA repair and apoptosis, thereby facilitating the growth and spread of tumors.

Additionally, mutations in the BRCA genes have attracted attention due to their association with familial pancreatic cancer syndromes. These mutations impair DNA repair mechanisms, increasing the likelihood of genomic instability and elevating the risk of developing pancreatic cancer. Recognizing the potential clinical implications of BRCA mutations is crucial, as it informs personalized treatment strategies and surveillance protocols for individuals at high risk of developing pancreatic cancer. This understanding of the complex molecular landscape of pancreatic carcinogenesis paves the way for targeted therapies and precision medicine approaches tailored to the unique genetic makeup of each patient [20].

Tumor microenvironment and stromal interactions

The tumor microenvironment (TME) in pancreatic cancer is a complex and dynamic landscape that plays a critical role in the progression and metastasis of the disease. It consists of various non-tumor cells, cytokines, growth factors, and proteins of the extra-

cellular matrix (ECM). One of the key features of the TME in pancreatic ductal adenocarcinoma (PDAC) is its highly fibrotic stroma, which contains a heterogeneous population of cancer-associated fibroblasts (CAFs). These CAFs are the primary producers of ECM components, with collagens being the most abundant. The deposition of collagens into the ECM forms fibrillar structures that not only provide structural support but also interact with cancer cell surface receptors, influencing signaling pathways that can lead to epithelial-to-mesenchymal transition (EMT) and metastasis [21].

Furthermore, the mechanical traits of the TME, such as tissue stiffness and solid stress, are influenced by the accumulation of collagens and other ECM components. These mechanical forces affect cell motility, and tumor microstructure, and can alter the response to therapeutic interventions. The interplay between the mechanical aspects of the TME and the biological responses of cancer cells is an area of intense research, as it holds the potential for developing new therapeutic strategies targeting the stromal interactions in PDAC [22].

In addition to the structural and mechanical components, the TME is also characterized by its involvement in metastasis. The interactions between pancreatic cancer cells and stromal cells, such as pancreatic stellate cells (PSCs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), contribute to an environment that supports tumor growth and resistance to conventional therapies. These cellular interactions facilitate processes like angiogenesis, lymph angiogenesis, invasion, migration, and the formation of pre-metastatic niches, which are crucial for the spread of cancer cells to distant organs [23].

Metastatic mechanisms and pathways

Pancreatic cancer (PC) is a formidable malignancy with a low prevalence rate but a high fatality rate, especially in its metastatic stage (stage IV). Patients often lack specific clinical manifestations, and most cases are inoperable at the time of diagnosis. Despite efforts to improve survival outcomes, understanding the molecular mechanisms of metastasis remains challenging. The review by Chen et al. provides insights into these mechanisms. Notably, several signaling pathways play crucial roles in PC metastasis:

- ***Epithelial-Mesenchymal Transition (EMT):*** EMT facilitates cancer cell migration and invasion by altering cell adhesion properties.
- ***NF-κB Pathway:*** Activation of NF-κB promotes tumor progression and metastasis.
- ***KRAS:*** Mutations in KRAS are common in PC and contribute to metastatic spread. Additionally, the review discusses imaging techniques for early detection (such as carbohydrate antigen 19-9) and potential biomarkers (including prostate cancer-associated transcript-1 and F-box/LRR-repeat protein 7) that could aid in managing metastatic PC [24-26].

Clinical Presentation and Diagnosis

Signs and symptoms of pancreatic cancer

Pancreatic malignancy often remains symptomless in its initial stages, posing a challenge for timely diagnosis. However, as the illness progresses, numerous distinctive indicators manifest. Individuals may encounter:

- ***Abdominal Discomfort:*** Initially, patients may report mild unease in the upper abdomen, which can later spread to the posterior region.
- ***Appetite Loss:*** A reduction in appetite is prevalent, leading to unintended weight decline.
- ***Jaundice:*** The skin and whites of the eyes may turn yellow (jaundice) due to blockage of the bile duct by the tumor.
- ***Gastrointestinal Disturbances:*** Irregular bowel movements, queasiness, retching, and alterations in bowel patterns may arise.
- ***Diabetes:*** The onset of new diabetes or deterioration in glycemic regulation could signal pancreatic malignancy.
- ***Itchiness:*** Pruritus may develop due to heightened bilirubin levels from bile duct obstruction.
- ***Blood Clots:*** Unexplained discomfort and swelling in an arm or leg might be linked to thrombosis [27, 28].

Diagnostic Modalities

Imaging

When evaluating and staging pancreatic carcinoma, various imaging techniques are commonly utilized. These methods aid in visualizing the pancreas and identifying any suspicious regions indicative of malignancy. Below are the primary imaging methodologies for pancreatic carcinoma:

Computed Tomography (CT) Scanning

CT scans produce intricate cross-sectional portrayals of anatomy.

They are frequently employed in diagnosing pancreatic carcinoma due to their ability to offer a clear depiction of the pancreas.

Moreover, CT scans can indicate whether the carcinoma has disseminated to neighboring organs, lymph nodes, or distant locales.

Specific varieties of CT scans, such as multiphase or pancreatic protocol CT scans, may be employed for more precise evaluation.

Magnetized Resonance Imaging (MRI)

MRI scans employ radio waves and robust magnets to generate detailed visualizations.

Though CT scans are favored for observing the pancreas, MRIs are occasionally utilized to search for minute metastatic lesions in the liver.

Special MRI methodologies, such as MR cholangiopancreatography (MRCP), can evaluate the pancreatic and bile ducts, while MR angiography (MRA) scrutinizes blood vessels.

Endoscopic Ultrasound (EUS)

EUS merges endoscopy with ultrasound to inspect the pancreas and its proximal structures.

It proves particularly valuable in identifying diminutive tumors and assessing the extent of cancer infiltration.

EUS-guided fine-needle aspiration (FNA) can procure tissue specimens for histological examination.

Endoscopic Retrograde Cholangiopancreatography (ERCP)

ERCP is an endoscopic intervention that surveys the pancreatic and bile ducts. It aids in diagnosing pancreatic carcinoma and managing specific complications, such as bile duct obstruction.

Throughout ERCP, a contrast medium is administered, and X-rays are captured to visualize the ductal system [29-31].

Biopsy

Liquid Biopsy Techniques for Pancreatic Cancer Diagnosis and Monitoring

Pancreatic cancer (PC) poses significant challenges due to late-stage diagnosis and limited treatment options. Liquid biopsy, a non-invasive detection method, has emerged as a promising tool for PC management.

- ***Circulating Tumor Cells (CTCs):*** These rare cells shed from the tumor into the bloodstream can provide valuable information about tumor biology and metastasis.
- ***Circulating Tumor DNA (ctDNA):*** Fragments of tumor DNA in the blood can be analyzed for genetic alterations, aiding early diagnosis and monitoring treatment response.
- ***Noncoding RNAs (ncRNAs):*** MicroRNAs and long noncoding RNAs are potential biomarkers for PC detection.

- ***Extracellular Vesicles (EVs) or Exosomes:*** These small vesicles carry tumor-specific molecules and can be isolated from blood samples for diagnostic purposes. Liquid biopsy holds promise for personalized treatment decisions and prognostic evaluation in PC.

Biopsy Techniques for Pancreatic Neoplasms: Obtaining tissue samples for accurate diagnosis is crucial in pancreatic neoplasms.

- ***Fine Needle Aspiration Biopsy (FNA):*** This minimally invasive procedure uses a thin needle to extract cells from the tumor for cytological examination.
- ***Tru-Cut Needle Biopsy:*** A larger-core needle is used to obtain tissue samples, allowing histopathological analysis.
- ***Endoscopic Brushings/Cytology:*** During endoscopy, a brush collects cells from the pancreatic duct for cytological evaluation.
- ***Endoscopic Ultrasound-Guided Biopsies:*** EUS-guided FNA or core biopsies provide high diagnostic accuracy and are useful for lesions near the gastrointestinal tract [34].

Tumor markers

Tumor markers play a crucial role in the diagnosis, prognosis, and monitoring of pancreatic cancer. Recent advancements in research have identified several promising biomarkers that show potential for improving the management of this challenging disease. Circulating tumor markers such as CA19-9 have long been utilized in clinical practice for pancreatic cancer detection and monitoring response to treatment. However, emerging evidence suggests the utility of novel biomarkers, including microRNAs and circulating tumor DNA, which offer enhanced sensitivity and specificity in detecting early-stage pancreatic cancer and predicting patient outcomes Additionally, the significance of combining multiple tumor markers in panel assays to improve diagnostic accuracy and prognostic assessment in pancreatic cancer patients not only increases the sensitivity of detection but also enables the stratification of patients into distinct risk groups, facilitating personalized treatment strategies [34].

Moreover, recent studies have focused on exploring the potential of tumor markers for predicting treatment response and guiding therapeutic decisions in pancreatic cancer emphasizing the role of dynamic changes in tumor marker levels during treatment as predictive indicators of treatment efficacy and disease progression. Integration of tumor marker monitoring into routine clinical practice may enable early identification of treatment resistance and prompt adjustment of therapeutic regimens, thereby improving patient outcomes.

These findings underscore the importance of ongoing research efforts in identifying and validating novel tumor markers to address the unmet clinical needs in pancreatic cancer management [34, 35].

Staging systems

TNM staging

TNM Staging System for Pancreatic Cancer: The TNM system is widely used for staging pancreatic cancer, providing critical information about tumor size, lymph node involvement, and distant metastasis. According to the American Joint Committee on Cancer (AJCC), the TNM system consists of three key components:

- ***T (Tumor Extent):*** Describes the size of the primary tumor and whether it has invaded nearby blood vessels or structures.
- ***N (Lymph Node Spread):*** Indicates whether cancer has spread to nearby lymph nodes and the number of affected nodes.
- ***M (Metastasis):*** Reflects distant spread to organs such as the liver, lungs, or bones. The AJCC's most recent staging system (effective January 2018) classifies pancreatic cancers from stage 0 (carcinoma in situ) to stages I through IV. Lower stage numbers indicate less extensive spread, while higher numbers signify advanced disease. Accurate staging guides treatment decisions and helps predict patient outcomes.

Clinical Implications and Numerical Staging: In addition to the TNM system, numerical staging (Roman numerals I to IV) is commonly used to characterize pancreatic cancer stages. The Canadian Cancer Society emphasizes that higher stage numbers correspond

to more extensive cancer spread. For instance:

- ***Stage I:*** Indicates localized cancer confined to the pancreas.
- ***Stage II:*** Suggests limited local spread beyond the pancreas.
- ***Stage III:*** Signifies more extensive local invasion and possible lymph node involvement.
- ***Stage IV:*** Represents distant metastasis. Accurate staging informs treatment planning, prognosis discussions, and clinical management decisions for patients with pancreatic cancer [36, 37].



Resect ability criteria

Determining Surgical Feasibility in Pancreatic Cancer: The question of whether pancreatic cancer is amenable to surgical resection is critical for treatment planning. To address this, experts have developed a classification system known as borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC). This classification considers three dimensions:

- ***Anatomical Criteria (A):*** These criteria assess tumor size and its relationship to nearby blood vessels. If the tumor has minimal impact on vessel function, it may be considered resectable.
- ***Biological Criteria (B):*** Patients meeting anatomical criteria but showing clinical signs suggestive of distant metastases fall into this category. Although metastasis is not confirmed, it raises caution.
- ***Conditional Criteria (C):*** Patients meeting anatomical criteria but having other factors (such as comorbidities) that affect surgical feasibility are classified as BR-PDAC. These cases require individualized assessment.

Staging Pancreatic Cancer for Treatment Decisions: The MD Anderson Cancer Center (MDACC) Pancreatic Cancer Group introduced subsets to characterize BR-PDAC resect ability further:

- ***BR-A Disease:*** Patients meeting anatomical criteria without additional clinical concerns.
- ***BR-B Disease:*** Although anatomically resectable, these patients exhibit clinical features suggestive of metastasis (based on bi-

opsy or imaging).

- ***BR-C Disease:*** Patients meeting anatomical criteria but facing other challenges affecting surgical feasibility. These subsets provide a nuanced assessment beyond anatomical considerations, aiding treatment decisions and prognostic discussions [38-40].

Challenges in early detection and screening

Addressing the challenges in early detection and screening of pancreatic cancer requires interdisciplinary collaboration and innovative approaches to improve patient outcomes.

Challenges in Early Detection

The frequency of ductal adenocarcinoma in the pancreas (PDAC) is escalating, and it is forecasted to emerge as the second principal cause of death related to cancer by 2030 [41]. Despite enhancements in operative methods and care during the peri-operative phase, the general survival rate for PDAC persists substandard. Early recognition is paramount, yet it poses numerous obstacles. One pivotal hurdle is the limited occurrence of PDAC in the overall populace, rendering extensive screening unfeasible2. Nonetheless, specific high-risk clusters, such as those with hereditary susceptibility to pancreatic cancer, fresh-onset hyperglycemia, mucinous cysts in the pancreas, and persistent pancreatitis, might gain from directed screening schemes [42]. Fluid biopsies, encompassing circulating vesicles, genetic material from tumors, and tumor cells, hold potential as diverse indicators for early identification, treatment direction, and surveillance for reappearance. Tailored medicine, delving into focused therapeutics for actionable alterations (for instance, PARP inhibitors for BRCA mutations) and immunotherapy tactics, presents another avenue for refining premature identification. Additionally, artificial intelligence (AI) is emerging as a potent instrument in medical visualizations, genetic explorations, and planning for treatment. Nonetheless, complications linked with AI incorporate ethical concerns, safeguarding of data, dependability of algorithms, and validation [43].

Screening Challenges

Although screening for pancreatic cancer is not advocated in the general populace due to its limited incidence, pinpointing high-risk persons remains crucial. High-risk cohorts involve those with a familial background of pancreatic cancer, hereditary anomalies (such as BRCA1/2), or pancreatic abnormalities (such as intraductal papillary mucinous neoplasms). Nevertheless, implementing efficient screening regimens poses a challenge. Present imaging techniques, like computed tomography (CT) and magnetic resonance imaging (MRI), play a crucial role in pinpointing premature, potentially treatable PDAC in high-risk assemblies [43].

Nevertheless, there exists a necessity for more sensitive and specific imaging approaches. Collaborative endeavors among medical practitioners, researchers, and AI specialists are indispensable for unleashing AI's potential to enrich pancreatic cancer management. Despite these hurdles, advancements in fluid biopsies, tailored medicine, and AI proffer optimism for enhancing the diagnosis, treatment, and oversight of pancreatic cancer [44, 45].

Treatment Modalities

Surgery

Surgical strategies for pancreatic malignancies, notably pancreatic ductal adenocarcinoma (PDAC), present significant challenges due to their poor survival rates and late detection. Surgical intervention remains the primary treatment option for PDAC patients, with several essential surgical methods utilized:

- ***Pancreaticoduodenectomy (PO)***, also referred to as the Whipple procedure, involves the removal of the pancreatic head, a segment of the small intestine, the gallbladder, and the bile duct. This procedure is commonly performed for tumors located in the pancreatic head.
- ***Pylorus Preserving Pancreaticoduodenectomy (PPPD)*** is a modified version of PO that aims to preserve the pylorus, thereby reducing postoperative complications.

- ***Distal Pancreatectomy (DP)*** is effective for tumors situated in the body or tail of the pancreas, involving the removal of the left portion of the pancreas.

These surgical techniques have undergone continuous improvement to enhance outcomes and minimize complications. Endoscopic pancreatic surgery has demonstrated superior patient outcomes and shorter postoperative recovery times. Advancements in robotic surgery have also overcome the limitations of standard endoscopy, enabling more precise dissection and reconstruction [46-48].

Nevertheless, clinically relevant pancreatic fistula remains a persistent challenge post-procedure, and efforts are underway to alleviate its impact on clinical outcomes.

In recent years, there has been increasing interest in minimal-access approaches to pancreatic cancer surgery, such as laparoscopic and robotic techniques. These approaches aim to reduce surgical trauma, expedite patient recovery, and improve overall outcomes. Researchers are summarizing existing surgical techniques and adapting them to minimally invasive frameworks. While patient outcome data continue to evolve, the focus remains on achieving curative-intent surgery for marginally resectable and locally advanced pancreatic cancer.

Collaboration among surgeons, researchers, and technology experts is essential to further refine these approaches and enhance the prognosis for patients confronting this challenging disease [44, 45].

Multimodal treatment concepts have expanded the options for surgery in locally advanced PDAC. Several technical innovations facilitate curative-intent resection:

- ***Artery-First and Uncinate-First Approaches:*** These techniques enhance the completeness of resection and reduce the risk of local recurrence.
- ***Anatomical Triangle Dissection:*** Focusing on the triangle between the coeliac and superior mesenteric arteries and the porto mesenteric vein improves surgical precision.
- ***Radical Antegrade Modular Pancreatosplenectomy:*** This approach contributes to achieving complete resection.
- ***Venous Involvement Management:*** Elaborated techniques allow resection even in patients with portal venous congestion and cavernous transformation.
- ***Arterial Involvement Adaptation:*** Recent methods address arterial involvement following neoadjuvant treatment.

These advanced techniques provide a toolkit for curative-intent surgery in borderline resectable and locally advanced PDAC. However, their impact on overall survival awaits high-level clinical evidence. Despite most patients presenting with advanced-stage disease, favorable downstaging potential from neoadjuvant therapy and the importance of local resection offer hope. Arterial resection can now be considered as part of surgery, thanks to these advancements [49, 50].

Chemotherapy: standard regimens and advancements

Clinical trials conducted in Japan where standard regimens include [51].

- ***FOLFIRINOX*** which is a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin was introduced in 2011.
- ***Gemcitabine plus nab-paclitaxel*** was established in 2013.
- ***Fluorouracil (FU)/nano liposomal irinotecan*** which was Introduced in 2016
- ***NALIRIFOX*** which is a very recent addition to cytotoxic regimens.

Over the last 12 years, significant advancements have been made for pancreatic cancer which include: [52]

- ***Switch Maintenance:*** Using cytotoxic therapies to prolong treatment benefits. To improve the outcome patients who respond well to the initial therapies will continue to maintain treatment
- ***Induction Maintenance:*** For patients with improved or stable disease after initial platinum-based therapy, induction/Mainte-

nance provides a chemotherapy-free option which is relatively less toxic even though no evidence suggests an improved survival rate.

- ***Targeted Agents:*** The KRAS inhibitors are promising when it comes to precision medicine even though the eligible patient remains small.
- ***Cytotoxic regimens:*** Notably NALIRIFOX which has shown promising outcomes during clinical trials.

For locally advanced Pancreatic cancer (LAPC) FOLFIRINOX and gemcitabine-based chemotherapy regimens have become standard of care because they aim to provide a better outcome [53].

Radiation therapy: techniques and outcomes

Radiation Therapy (RT) is effective in managing resectable and locally advanced Pancreatic cancer. The recent progress regarding the treatment regimen, the mode of the treatment, and combination approaches have gained prominence especially considering half of patients with resectable pancreatic cancer can't receive adjuvant therapy because of surgical complications, prolonged recovery time and early recurrence. The inclusion of radiation therapy in the neoadjuvant setting is still debatable. RT is promising since Modifying the microenvironment of the tumor and improving resectable rates makes Radiation therapy promising. However, there is still an ongoing debate regarding the benefit of resected pancreatic cancer [54].

A comprehensive understanding of radiation dose increment strategies and novel neoadjuvant therapy approaches are essential in improving outcomes in pancreatic cancer. Recent studies focused on Optimizing radiation therapy for locally advanced pancreatic cancer and improving outcomes for resectable and borderline resectable cases. Increasing the dose focuses on maximizing tumor control while minimizing toxicity.

Neoadjuvant therapies have gained traction as they focus on improving surgical outcomes by downgrading tumors and facilitating resection. Despite these advances, the role of RT In managing pancreatic cancer is still debatable. The interplay between the connective tissue, immune, and vascular components around the tumor further complicates the decision-making process pointing out the importance of collaboration between clinicians, researchers, and patients in improving the field of RT and patient care [55].

Targeted therapy: molecularly targeted agents and inhibitors

Molecularly Targeted Agents in Pancreatic Cancer Therapy Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to its poor prognosis and high mortality rate. Recent advancements in precision oncology have highlighted the role of molecular alterations as potential therapeutic targets. Next-generation sequencing (NGS) enables the identification of aberrant genetic mutations and altered pathways specific to PDAC. Three key approaches emerge for targeted therapy in PDAC:

- ***Oncogene Inhibition***: Dysregulated oncogenes, including KRAS, NRG1, and NTRK, play pivotal roles in tumorigenesis. Researchers are exploring strategies to simultaneously inhibit multiple molecules or pathways, modify mutant residues using small molecules, and employ RNA interference. However, challenges persist, and emerging approaches are essential.
- ***Tumor Suppressor Reactivation***: TP53, CDKN2A, and SMAD4 are major tumor suppressors implicated in PDAC. Clinical trials targeting these genes have shown promise. Molecular subtyping based on SMAD4 mutation status holds the potential for precision oncology.
- ***Chromosomal Stability Restoration***: Genes such as KDM6A and BRCA, crucial for maintaining chromosomal stability, are deficient in some PDAC patients. Correcting these deficiencies through targeted therapy shows encouraging outcomes, as seen in the POLO trial with the PARP inhibitor Olaparib. Additionally, immunotherapies, including CAR-T cells and immune checkpoint inhibitors, exhibit potential but remain limited in clinical value for PDAC1 [56].

Challenges and Future Directions Despite progress, challenges persist in targeted therapy for pancreatic cancer. Tumor heterogeneity, adaptive responses, and off-target effects necessitate personalized approaches. Precision medicine guided by biomarkers, liquid biopsies, and next-gene sequencing holds promise. Immunotherapies, though limited, synergize with targeted agents. Integrating

targeted therapies into multimodal regimens, optimizing patient outcomes, and overcoming resistance mechanisms remain critical research directions. As we unravel the complexities of PDAC biology, collaborative efforts between clinicians, researchers, and patients will shape the future of precision oncology for this challenging malignant [57, 58].

Immunotherapy

Immunotherapy in Pancreatic Cancer remains a formidable adversary with limited effective treatment options. Clinical trials targeting immune checkpoint molecules have yielded encouraging results. However, several intrinsic features of pancreatic cancer, such as its low mutational load and highly immunosuppressive desmoplasia, pose challenges to immunotherapy efficacy. Despite these hurdles, ongoing research aims to unravel the complexities of tumor immunology and tailor therapeutic strategies. In this review, we summarize current immunotherapeutic approaches and discuss clinical trials focusing on checkpoint inhibitors. Additionally, we explore emerging trends, including combinations with therapies targeting immunosuppressive myeloid cells [59].

Emerging Strategies and Future Directions The landscape of immunotherapy for pancreatic cancer is rapidly evolving. Researchers are investigating novel approaches to overcome resistance and enhance treatment outcomes. Combinatorial strategies hold promise, aiming to maximize the potential of immunotherapy. These include:

- ***Myeloid Cell Targeting***: Efforts are underway to modulate the tumor microenvironment by addressing immunosuppressive myeloid cells. Combinations with agents that reprogram or deplete these cells may enhance immunotherapy responses.
- ***Precision Medicine***: Biomarker-driven selection and personalized treatment regimens are critical. Identifying predictive markers and tailoring therapy based on individual patient characteristics will optimize outcomes.
- ***Immunotherapies Beyond Checkpoints***: Beyond checkpoint inhibitors, other immunotherapies (such as cancer vaccines, adoptive T cell therapies, and cytokine-based approaches) are being explored. As we navigate the complexities of pancreatic cancer, collaborative efforts between researchers, clinicians, and patients will shape the future of immunotherapy, offering hope for improved outcomes and prolonged survival [59, 60].

References

1. Siegel RL, Miller KD and Jemal A. “Cancer statistics, 2020”. CA: A Cancer Journal for Clinicians 70.1 (2020): 7-30.
2. Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: A Cancer Journal for Clinicians 68.6 (2018): 394-424.
3. American Cancer Society. Cancer Facts & Figures 2020. Atlanta, GA: American Cancer Society (2020).
4. Benzel J and Fendrich V. “Familial Pancreatic Cancer”. Oncology Research and Treatment 41.11 (2018): 611-618.
5. Sung H., et al. “Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry”. The Lancet Public Health 4.3 (2019): e137-e147.
6. Pereira SP., et al. “Early detection of pancreatic cancer”. Lancet Gastroenterology & Hepatology (2020).
7. Naudin S., et al. “Healthy lifestyle and the risk of pancreatic cancer in the EPIC study”. European Journal of Epidemiology (2020).
8. Raimondi S, Maisonneuve P and Lowenfels AB. “Epidemiology of pancreatic cancer: An overview”. Nature Reviews Gastroenterology & Hepatology 6.12 (2009): 699-708.
9. Stoffel EM, Brand RE and Goggins M. “Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention”. Gastroenterology 164.4 (2023): 752-765.
10. Gaddam S., et al. “Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018”. JAMA 326.20 (2021): 2075-2077.
11. Fonseca AL., et al. “Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review”. Ann Surg Oncol 29 (2022): 3232-3250.
12. Silva-Santiseban A., et al. “Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: A systematic review and meta-analysis”. Gastrointestinal Endoscopy (2024).
13. Hu J-X., et al. “Pancreatic cancer: A review of epidemiology, trend and risk factors”. World Journal of Gastroenterology 27.27

(2021): 4298-4231.

14. Maisonneuve P and Lowenfels AB. "Risk factors for pancreatic cancer: A summary review of meta-analytical studies". International Journal of Epidemiology 44.1 (2015): 186-198.
15. Maisonneuve P and Lowenfels AB. "Risk factors for pancreatic cancer: A summary review of meta-analytical studies". International Journal of Epidemiology 44.1 (2015): 186-198.
16. Stoffel EM, Brand RE and Goggins M. "Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention". Gastroenterology 164 (2023): 752-765.
17. Kadlubar FF., et al. "Comparison of DNA adduct levels associated with oxidative stress in human pancreas". Mutation Research 405 (1998): 125-133.
18. Thompson PA., et al. "Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype". Mutation Research 424 (1999): 263-274.
19. Li D., et al. "DNA adducts, genetic polymorphisms, and K-ras mutations in human pancreatic cancer". Mutation Research (2022): 513.37-48.
20. Sohn TA and Yeo CJ. "The molecular genetics of pancreatic ductal carcinoma: a review". Surgical Oncology 9.2 (2000): 95-101.
21. Sakorafas GH and Tsiotos GG. "Molecular biology of pancreatic cancer: potential clinical implications Bio Drugs 15.7 (2001): 439-452.
22. Maneshi P., et al. "Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits". Frontiers in Cell and Developmental Biology 9 (2021).
23. Ren B., et al. "Tumor microenvironment participates in metastasis of pancreatic cancer". Molecular Cancer 17.1 (2018): 108.
24. Joshi VB., et al. "The Cell Biology of Metastatic Invasion in Pancreatic Cancer: Updates and Mechanistic Insights". Cancers 15.7 (2023): 2169.
25. Guo Z., et al. "Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance". Cancer Metastasis Rev (2024).
26. Chen X., et al. "Metastatic pancreatic cancer: Mechanisms and detection". Oncology Reports (2021): 231.
27. Mayo Clinic. (n.d.). "Pancreatic cancer - Symptoms and causes". Retrieved from Mayo Clinic.
28. American Family Physician (AAFP). (n.d.). Pancreatic Cancer: Rapid Evidence Review.
29. Lee JM and Yoon JH. "Imaging Diagnosis of Pancreatic cancer: CT and MRI". In Pancreatic cancer (2017): 1926.
30. Al-Hawary M. "Role of Imaging in Diagnosing and Staging Pancreatic Cancer". Journal of the National Comprehensive Cancer Network 14.5S (2016).
31. Chouksey A and Satishchand JP. "New Imaging Modalities for Early Diagnosis of Pancreatic Cancer". iCliniq (2023).
32. Al-Hawary M. "Assessment of pancreatic neoplasms: Review of biopsy techniques". Journal of Gastrointestinal Surgery 11.5 (2007): 654-662.
33. Wang K., et al. "Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation". Molecular Cancer 22 (2023): 167.
34. Gai X, Zhou C and Song Q. "Advances in pancreatic cancer biomarkers". Expert Review of Molecular Diagnostics 20.6 (2020): 609-622.
35. Jia S., et al. "Role of tumor markers in predicting the efficacy of chemotherapy in pancreatic cancer: A review". Frontiers in Oncology 12 (2022): 772643.
36. onco.com. TNM Staging of Pancreatic Cancer (2018).
37. Canadian Cancer Society. (n.d.). Stages of pancreatic cancer.
38. Isaji S., et al. "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma". Pancreatology 17.5 (2017): 639-648.
39. Al-Hawary M. "Imaging assessment of pancreatic cancer resect ability after neoadjuvant therapy". American Journal of Roentgenology 210.1 (2018): 45-52.
40. Katz MHG and Wolfgang CL. "Current concepts in the treatment of resectable pancreatic cancer". Current Oncology Reports 22.9

(2020): 91.

41. Daamen LA, Molenaar IQ and Groot VP. "Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine, and Artificial Intelligence". Journal of Clinical Medicine 12.23 (2023): 7485.
42. Garg Sushil Kumara and Chari Suresh TB. "Early detection of pancreatic cancer". Current Opinion in Gastroenterology 36.5 (2020): 456-461.
43. Oldfield L., et al. "Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for Protein Biomarkers". In: Michalski, C., Rosendahl, J., Michl, P., Kleeff, J. (eds) Translational Pancreatic Cancer Research. Molecular and Translational Medicine. Humana, Cham (2020).
44. Singhi AD., et al. "Early Detection of Pancreatic Cancer: Opportunities and Challenges". Gastroenterology 156.7 (2019): 2024-2040.
45. Farr KP., et al. "Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities". Cancers 14.10 (2022): 2539.
46. Di Martino M and El Boghdady M. "Pancreatic cancer surgery". BMC Surg 23 (2023): 196.
47. Ricky H Bhogal, Stephanos Pericleous and Aamir Z Khan. "Open and Minimal Approaches to Pancreatic Adenocarcinoma". Gastroenterology Research and Practice 2020 (2020).
48. Shah OJ and Singh M. "Developments in pancreatic cancer surgery". Updates Surg 76 (2024): 17-22.
49. M Schneider., et al. "Technical advances in surgery for pancreatic cancer". British Journal of Surgery 108.7 (2021): 777-785.
50. Kasumova GG, Conway WC and Tseng JF. "The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery". Ann Surg Oncol 25 (2018): 51-58.
51. Okusaka T and Furuse J. "Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines". J Gastroenterol 55 (2020): 369-382.
52. Timothy J Brown., et al. "Advancements in systemic Therapy for pancreatic cancer". Am Soc Clin Oncol Educ Book 43 (2023): e397082.
53. Malinosky HR, Stewart JH and Moaven O. "Current Approaches to the Management of Locally Advanced Pancreatic Cancer". Curr Surg Rep 11 (2023): 260-269.
54. Malla M., et al. "The evolving role of radiation in pancreatic cancer". Frontiers in Oncology 12 (2022): 1060885.
55. Liu J., et al. "Advances in Radiation Oncology for Pancreatic Cancer: An Updated Review". Cancers 14.23 (2022): 5725.
56. Qian Y., et al. "Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma". J Hematology Oncol 13 (2020): 130.
57. Dai H., et al. "Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy". Frontiers in Cell and Developmental Biology 10 (2022): 855474.
58. Zagouri, Flora., et al. "Molecularly Targeted Therapies in Metastatic Pancreatic Cancer: A Systematic Review". Pancreas 42.5 (2013): 760-773.
59. Cheung PF, Lutz M and Siveke JT. "Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends". Oncology Research and Treatment 41.5 (2018): 286-290.
60. Brouwer TP, Vahrmeijer AL and de Miranda NFCC. "Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel". Cell Oncol 44 (2021): 261-278.